Available options for glycemic management in T2D include not only exogenous insulin, but also a spectrum of pharmacologic agents whose actions include augmentation of insulin sensitivity, stimulation of insulin secretion, and slowing of intestinal glucose absorption. This evidence concerns the gene INS and type 2 diabetes mellitus.